Genmab — Februar 2018
-
Så skal jeg da love for at inflationstallene ramte aktiemarkedet

-
-
AQR øger til
1,93% -
De nærmer sig 1,3 mill.

-
Tjahhh...den stiger da igen..
-
Ja det tog ikke ret længe for den at rette sig

-
-
Dara en (lille) del af dette nye studie i "Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer".https://clinicaltrials.gov/ct2/show/NCT03432741?term=daratumumab&sfpd_s=02%2F01%2F2018&sfpd_e=02%2F14%2F2018&rank=1
-
Tror altså ikke man skal lægge meget i den AQR position. De bruger blandt andet momentum til at identificere long/short kandidater.. og meget kan man sige om GEN, men momentum kniber det altså lidt med for tiden. Min opfattelse er, at vi her kigge mere på de fundamentale og og med en horisont, som er noget længre end AQR.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind